9.03

2.59% -0.24

Adaptive Biotechnologies Corp (ADPT)

Overview News Price History Option Chain Financials Why ADPT Down? Discussions Forecast

Adaptive Biotechnologies Corp stock is traded at $9.03, with a volume of 1.15M. It is down -2.59% in the last 24 hours and up +7.76% over the past month. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Previous Close:

$9.27

Open:

$9.4

24h Volume:

1.15M

Relative Volume:

0.49

Market Cap:

$1.49B

Revenue:

$177.28M

Net Income/Loss:

$-195.24M

P/E Ratio:

-6.7388

EPS:

-1.34

Net Cash Flow:

$-114.54M

1W Performance:

-8.23%

1M Performance:

+7.76%

6M Performance:

+55.15%

1Y Performance:

+153.65%

1-Day Range:

$9.025

$9.5029

1-Week Range:

$8.375

$10.20

52-Week Range:

$2.99

$10.28

Adaptive Biotechnologies Corp Stock (ADPT) Company Profile

Name

Adaptive Biotechnologies Corp

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

206-659-0067

Address

1165 EASTLAKE AVE E, SEATTLE, WA

Employee

619

Twitter

@adaptivebiotech

Next Earnings Date

2025-02-11

Latest SEC Filings

ADPT's Discussions on Twitter

Compare ADPT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADPT Adaptive Biotechnologies Corp	9.03	1.49B	177.28M	-195.24M	-114.54M	-1.34
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-21-25	Upgrade	Goldman	Neutral → Buy
Jul-05-23	Resumed	JP Morgan	Overweight
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Dec-21-22	Upgrade	Piper Sandler	Neutral → Overweight
Aug-25-22	Initiated	Credit Suisse	Underperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Feb-16-22	Reiterated	BTIG Research	Buy
Feb-16-22	Reiterated	BofA Securities	Buy
Feb-16-22	Reiterated	Goldman	Neutral
Feb-16-22	Reiterated	JP Morgan	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Mar-03-21	Downgrade	Goldman	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight
Jun-03-20	Initiated	Goldman	Buy
Jul-23-19	Initiated	BTIG Research	Buy
Jul-22-19	Initiated	BofA/Merrill	Buy
Jul-22-19	Initiated	Cowen	Outperform
Jul-22-19	Initiated	Goldman	Neutral
Jul-22-19	Initiated	Guggenheim	Buy
Jul-22-19	Initiated	William Blair	Outperform

View All

Adaptive Biotechnologies Corp Stock (ADPT) Latest News

May 09, 2025

Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy? - Yahoo Finance

May 09, 2025

May 08, 2025

Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year? - Yahoo Finance

May 08, 2025

Brokerages Set Adaptive Biotechnologies Co. (NASDAQ:ADPT) Price Target at $9.50 - Defense World

May 08, 2025

May 07, 2025

Trading Day Review: Adaptive Biotechnologies Corp (ADPT) Loses Momentum, Closing at 8.81 - DWinneX

May 07, 2025

MetLife Investment Management LLC Acquires 3,650 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World

May 07, 2025

May 06, 2025

Adaptive Biotechnologies (ADPT) Price Target Raised by Piper Sandler | ADPT Stock News - GuruFocus

May 06, 2025

Adaptive Biotechnologies Reaches Analyst Target Price - Nasdaq

May 06, 2025

ADPT Price Target Increased to $13 by Piper Sandler | ADPT Stock News - GuruFocus

May 06, 2025

Adaptive Biotechnologies (NASDAQ:ADPT) Sees Unusually-High Trading Volume Following Analyst Upgrade - Defense World

May 06, 2025

Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $9.00 at Morgan Stanley - Defense World

May 06, 2025

May 05, 2025

Adaptive Biotechnologies (ADPT) Price Target Raised by Morgan St - GuruFocus

May 05, 2025

5 Analysts Assess Adaptive Biotechnologies: What You Need To Know - Benzinga

May 05, 2025

Adaptive Biotechnologies Corp (NASDAQ: ADPT) Stock Forecast: Downside Of -42.28% By 2025 - Stocksregister

May 05, 2025

Adaptive Biotechnologies (ADPT) Price Target Raised by Morgan Stanley | ADPT Stock News - GuruFocus

May 05, 2025

Adaptive Biotechnologies (ADPT) Price Target Increased by Morgan Stanley | ADPT Stock News - GuruFocus

May 05, 2025

Adaptive Biotechnologies Co. (NASDAQ:ADPT) Stock Position Lifted by Wells Fargo & Company MN - Defense World

May 05, 2025

Adaptive Biotechnologies Soars 120% In 9 MonthsCan The Momentum Continue? - RTTNews

May 05, 2025

May 04, 2025

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.57 - Yahoo Finance

May 04, 2025

May 03, 2025

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2025 Earnings Call Transcript - Insider Monkey

May 03, 2025

Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 12-Month High Following Earnings Beat - Defense World

May 03, 2025

Decoding Adaptive Biotechnologies Corp (ADPT): A Strategic SWOT Insight - GuruFocus

May 03, 2025

May 02, 2025

Adaptive Biotechnologies stock soars on Q1 earnings beat By Investing.com - Investing.com Canada

May 02, 2025

Adaptive Biotechnologies stock soars on Q1 earnings beat - Investing.com

May 02, 2025